Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Makers Rush to Apply for Anthrax as Additional Indication
November 19, 2001
- BI's Equity Stake in SSP exceeds 50%
November 12, 2001
- NEW PRODUCTS NEWS IN BRIEF
November 12, 2001
- Similar Function Comparison Method for Medical Materials Proposed
November 12, 2001
- AstraZeneca to Increase Share in Japan to 1.7% at End of 2001: CE McKillop
November 12, 2001
- Terumo Licenses New APD System from Debiotech of Spain
November 12, 2001
- BUSINESS NEWS IN BRIEF
November 12, 2001
- GL for Global Drug Development Needed: JPMA Expert
November 12, 2001
- Makers Providing More Products in Small Packages: Yano Report
November 12, 2001
- Approval Process for Medical Devices to Be Reviewed
November 12, 2001
- Sankyo Receives Approvable Letter for CS-866 from US FDA
November 12, 2001
- Fresenius: New APD System "sleep・safe"
November 12, 2001
- Sumitomo's Half-year Sales Top \69.2 Bil., Up \9 Bil.: President Yokotsuka
November 12, 2001
- GEMS Targeting Double-Digit Growth in Japanese Market: President Hogan
November 12, 2001
- EFPIA-EBC Position Statement: Japan（2）
November 12, 2001
- JACDS to Hold Self-medication Summit
November 12, 2001
- EFPIA-EBC Position Statement: Japan（1）
November 12, 2001
- Comprehensive Research Necessary in Psychiatry: Seminar
November 12, 2001
- ARB Effective for Heart Failure: Novartis Lecture
November 12, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 12, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…